TY  - CHAP
M1  - Book, Section
TI  - Cutaneous Drug Eruptions
A1  - Curry, Jonathan L.
A1  - Chu, Emily Y.
A1  - Tetzlaff, Michael T.
A2  - Barnhill, Raymond L.
A2  - Crowson, A. Neil
A2  - Magro, Cynthia M.
A2  - Piepkorn, Michael W.
A2  - Kutzner, Heinz
A2  - Desman, Garrett T.
PY  - 2020
T2  - Barnhill's Dermatopathology, 4e
AB  - Advances  in  molecular  techniques  and  the  ability  to  perform  deep  cancer  phenotyping  has  ushered  in  the  era  of  precision  cancer  medicine.1  The  field  of  medical  oncology  has  witnessed  a  paradigm  shift  in  the  treatment  of  cancer  with  targeted  cancer  therapy  with  small  molecule  inhibitors  (Nibs)  and  monoclonal  antibodies  (Mabs).  Given  the  frequency  of  adverse  cutaneous  reactions  encountered  from  Nibs  and  Mabs,  the  field  of  dermatopathology  has  now  entered  an  era  of  “oncologic  dermatopathology.”  As  a  result,  increasingly  dermatopathologists  are  confronted  with  a  diverse  array  of  adverse  cutaneous  reactions  developing  in  patients  undergoing  novel  anticancer  treatments.  Knowledge  of  the  clinical  features  of  these  adverse  reactions  will  aid  dermatopathologists  in  making  accurate  diagnoses.  
SN  - 
PB  - McGraw Hill Education
CY  - New York, NY
Y2  - 2024/04/23
UR  - dermatology.mhmedical.com/content.aspx?aid=1178398187
ER  -